Skip to main content

FENC

Stock
Health Care
Biotechnology

Performance overview

FENC Price
Price Chart

Forward-looking statistics

Beta
0.94
Risk
55.70%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.

Company info

SectorHealth Care
IndustryBiotechnology
Employees29
Market cap$187.4M

Fundamentals

Enterprise value$225.9M
Revenue$30.9M
Revenue per employee—
Profit margin-46.71%
Debt to equity-3.29

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.53
Dividend per share—
Revenue per share$1.13
Avg trading volume (30 day)$802K
Avg trading volume (10 day)$767K
Put-call ratio—

Macro factor sensitivity

Growth-1.4
Credit+21.5
Liquidity-3.8
Inflation-4.2
Commodities-2.6
Interest Rates-2.0

Valuation

Dividend yield0.00%
PEG Ratio23.78
Price to sales8.00
P/E Ratio23.78
Enterprise Value to Revenue7.31
Price to book-41.27

Upcoming events

Next earnings dayMay 13, 2025
Next dividend day—
Ex. dividend day—

News

Adherex Technologies Inc. (FENC) Reports Q1 Loss, Tops Revenue Estimates

Adherex Technologies Inc. (FENC) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to earnings of $0.41 per share a year ago.

Zacks Investment Research (May 13, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free